Free Trial
NASDAQ:MTVA

MetaVia (MTVA) Stock Price, News & Analysis

MetaVia logo
$0.69 -0.02 (-2.80%)
As of 10:41 AM Eastern

About MetaVia Stock (NASDAQ:MTVA)

Key Stats

Today's Range
$0.69
$0.71
50-Day Range
$0.62
$0.88
52-Week Range
$0.60
$5.04
Volume
13,518 shs
Average Volume
356,742 shs
Market Capitalization
$13.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.50
Consensus Rating
Buy

Company Overview

MetaVia Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

MTVA MarketRank™: 

MetaVia scored higher than 35% of companies evaluated by MarketBeat, and ranked 753rd out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MetaVia has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MetaVia has only been the subject of 2 research reports in the past 90 days.

  • Read more about MetaVia's stock forecast and price target.
  • Earnings Growth

    Earnings for MetaVia are expected to grow in the coming year, from ($3.90) to ($1.64) per share.

  • Price to Book Value per Share Ratio

    MetaVia has a P/B Ratio of 0.75. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MetaVia's valuation and earnings.
  • Short Interest

    There is no current short interest data available for MTVA.
  • Dividend Yield

    MetaVia does not currently pay a dividend.

  • Dividend Growth

    MetaVia does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for MTVA.
  • News Sentiment

    MetaVia has a news sentiment score of -0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for MetaVia this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, MetaVia insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 0.80% of the stock of MetaVia is held by insiders.

  • Percentage Held by Institutions

    Only 1.37% of the stock of MetaVia is held by institutions.

  • Read more about MetaVia's insider trading history.
Receive MTVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MetaVia and its competitors with MarketBeat's FREE daily newsletter.

MTVA Stock News Headlines

Google did what!?!?
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.
See More Headlines

MTVA Stock Analysis - Frequently Asked Questions

MetaVia's stock was trading at $2.03 at the beginning of the year. Since then, MTVA shares have decreased by 66.0% and is now trading at $0.69.

MetaVia Inc. (NASDAQ:MTVA) released its earnings results on Wednesday, May, 14th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.57) by $0.21.

Shares of MTVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/14/2025
Today
7/15/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MTVA
CIK
1638287
Employees
8
Year Founded
N/A

Price Target and Rating

High Price Target
$12.00
Low Price Target
$3.00
Potential Upside/Downside
+987.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$27.59 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-222.13%
Return on Assets
-123.85%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.55
Quick Ratio
1.55

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.92 per share
Price / Book
0.75

Miscellaneous

Outstanding Shares
19,589,000
Free Float
19,432,000
Market Cap
$13.52 million
Optionable
N/A
Beta
0.21
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:MTVA) was last updated on 7/15/2025 by MarketBeat.com Staff
From Our Partners